Transforming viral proteins such as E1A which force quiescent cells into S phase have two essential cellular target proteins, Rb and CBP/p300. Rb regulates the G1/ S transition by controlling the transcription factor E2F. CBP/p300 is a transcriptional co-activator with intrinsic histone acetyl-transferase activity. This activity is regulated in a cell cycle dependent manner and shows a peak at the G1/S transition, suggesting a function for CBP/p300 in this crucial step of the cell cycle. Here, we have arti®cially modulated CBP/p300 levels in individual cells through microinjection of speci®c antibodies and expression vectors. We show that CBP/p300 is required for cell proliferation and has an essential function during the G1/S transition. Using the same microinjection system and GFP-reporter vectors, we demonstrate that CBP/p300 is essential for the activity of E2F, a transcription factor that controls the G1/S transition. In addition, our results suggest that CBP HAT activity is required both for the G1/S transition and for E2F activity. Thus CBP/p300 seems to be a versatile protein involved in opposing cellular processes, which raises the question of how its multiple activities are regulated.
Introduction
The G1 phase is a key moment in the cell cycle for control of cell fate. Indeed, it is during G1 that the orientation of individual cells is programmed: beyond the G1/S transition, cells continue their progression in the cell cycle in an autonomous manner. Transforming viral proteins ± such as E1A or SV40 T ± which force the cells into S phase have essentially two intracellular protein targets, CBP/p300 and Rb (Dyson et al., 1989; Arany et al., 1995) . These two proteins are considered to be key elements in cell fate control (Giles et al., 1998; Goldman et al., 1997; Magnaghi-Jaulin et al., 1999) . The anti-oncogene product Rb controls E2F, a transcription factor that is central to the G1/S transition: E2F activates a subset of genes whose products are involved either in DNA synthesis, such as DNA polymerase alpha and proteins of the origin of replication complex (DeGregori et al., 1995; Hateboer et al., 1998) , or in cell cycle control, such as cyclin-E or Bmyb (Bennett et al., 1996; DeGregori et al., 1995; Lam and Watson, 1993) . Rb represses E2F in dierentiating cells or during early G1 (Chellappan et al., 1991; Nevins, 1998) . Progressive phosphorylation of Rb by the cyclin-dependent kinases results in Rb inactivation at the restriction point, allowing E2F target gene transcription. E2F repression by Rb involves a histone-deacetylase (Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998) and is crucial for cell cycle arrest by various cytokines (Zhang et al., 1999) . CBP and p300 are two highly homologous proteins (referred to as CBP/p300) that behave as transcriptional co-activators (Kwok et al., 1994) and cooperate with a number of sequence-speci®c transcription factors (Janknecht and Hunter, 1996) . CBP/p300 acts by providing a bridge between these factors and the basal machinery of transcription (Kee et al., 1996; Nakajima et al., 1997) . In addition, CBP/p300 has an intrinsic histone acetyltransferase (HAT) activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) and is also able to cooperate with transcription factors through chromatin remodelling or through the modi®cation of non-histone proteins involved in transcription (Chiarugi et al., 1998; Wole and Pruss, 1996) . CBP/p300 is a dual co-activator, acting both as a bridge and through remodelling chromatin or acetylating transcription factors. CBP/p300 cooperates with some transcription factors through its bridging activity, in the absence of its HAT domain (Korzus et al., 1998; Puri et al., 1997b; Ramirez et al., 1997; Swope et al., 1996) ; for other factors, such as CREB (Korzus et al., 1998) , the HAT domain is indispensable. CBP/p300 is found in large molecular complexes which also include other histone acetyl-transferases such as P/CAF (Yang et al., 1996) .
We have shown that CBP HAT activity is regulated in a cell cycle dependent manner, likely through phosphorylation by the Cyclin E-cdk2 complex (AitSi-Ali et al., 1998a). The activity is maximal at a time point preceding the G1/S transition. The function of this enzymatic activation is not understood. Given that CBP/p300 is a co-activator for E2F (Bernards, 1997; Fry et al., 1999; Lee et al., 1998; Nevins et al., 1997; Trouche et al., 1996) , these results led us to propose a model in which, near the G1/S transition, CBP is recruited to E2F target promoters in an activated form (Ait-Si-Ali et al., 1998a). Results described here provide experimental arguments in support of this model. First, we demonstrate that CBP or p300 is required for the G1/S transition and for E2F transcriptional activity, using experiments in which anti-CBP/p300 antibodies were microinjected into synchronized individual cells, with or without expression vectors for CBP. Second, we provide evidence that CBP/p300 HAT enzymatic activity is involved in this process. Our results indicate that CBP/p300 is a versatile molecule involved both in cell proliferation and in cell dierentiation, and raise the question of its regulation.
Results

CBP/p300 is required for the G1/S transition
In order to assess the function of CBP/p300 in cell proliferation, synchronized serum-deprived NIH3T3 cells were microinjected with anti-CBP/p300 antibodies and allowed to progress in the cell cycle by addition of serum. Entry into S phase was monitored 12 h later by BrdU incorporation. Anti-CBP/p300 antibodies drastically reduced the proportion of cells able to enter S phase, where irrelevant antibodies at similar concentrations (data not shown) had no eect (Figure 1 ). The lack of BrdU incorporation may be due to a delay in S phase entry (at least 36 h, data not shown) or to a complete block; but in any case, these data suggest that CBP and/or p300 is involved in the G1/S transition. Antibodies, however, can have non-speci®c eects in cells. In order to demonstrate that the antibodies were inhibiting the G1/S transition by blocking CBP/p300, re-expression of CBP/p300 was induced by co-microinjection of expression vectors. Cells were microinjected with anti-CBP/p300 or irrelevant antibodies, together with an expression vector for CBP, or an empty vector used as a negative control. Re-expression of CBP restored to normal levels the proportion of cells in S phase (Figure 1 ), whereas the empty control vector did not have any eect. This indicates that the antibodies indeed inhibit the G1/S transition by acting on CBP/ p300, likely by trapping the protein in the cytoplasm. Taken together, these results demonstrate without ambiguity that CBP/p300 is required for the G1/S transition and hence for cell proliferation.
CBP/p300 is required for E2F transcriptional activity
We next investigated the involvement of CBP/p300 in the G1/S transition at the molecular level. The G1/S transition is orchestrated, at least in large part, by the transcription factor E2F, under the control of the tumour suppressor Rb (Nevins, 1998; Weinberg, 1992) . Results from transient transfection experiments have previously suggested that CBP/p300 was able to cooperate with E2F (Fry et al., 1999; Lee et al., 1998; Trouche et al., 1996) . Therefore, the requirement for CBP/p300 at the G1/S transition could re¯ect the necessity of CBP/p300 for E2F activity. In order to test this hypothesis, cells were microinjected with a GFP reporter vector under the control of E2F binding sites, together with recombinant E2F-1 and either anti-CBP/ p300 or irrelevant antibodies. Exogenous E2F-1 readily activated the E2F-GFP reporter (Figure 2b ). Anti-CBP/p300 antibodies strongly repressed GFP expression, whereas irrelevant antibodies had no eect. This suggests that CBP and/or p300 are required for E2F activity. Normal levels of GFP expression were restored by the co-microinjection of a CBP expression vector, demonstrating as above the speci®city of the inhibition. Taken together, our results show that CBP and/or p300 are required for E2F activity during the progression from G1 to S phase.
Next, we investigated further the mechanism used by CBP/p300 to cooperate with E2F during the G1/S transition.
A deletion mutant of CBP with impaired HAT activity but normal E2F-1 and TBP binding CBP/p300 interacts with factors from the basal transcriptional machinery, and in particular with and TBP (Kwok et al., 1994; Swope et al., 1996) , an interaction that is important for co-activation (Swope et al., 1996) . In addition, CBP/p300 has intrinsic histone acetyl-transferase activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) , and HAT activity seems to be involved in the cooperation with the c-AMP responsive transcription factor CREB (Korzus et al., 1998) . CBP/p300 may thus cooperate with E2F by providing a molecular bridge between E2F and TBP or by modifying histone tails. In order to discriminate between these two possible mechanisms, we designed a mutant of CBP in which residues that are highly conserved among distant species (Shi and Mello, 1998) have been deleted from the HAT domain (CBPDHAT, Figure 3a ). This mutant indeed does not have any detectable HAT activity (Figure 3b ). It does, however, retain a normal capacity of interacting with E2F-1 or with the general transcription factor TBP, as indicated by GST pull down experiments (Figure 3c ). In order to rule out possible nonspeci®c charge interactions that can be observed in GST-pull down assays, we have also performed coimmunoprecipitation experiments from extracts of transfected cells. Results (Figure 3d ) demonstrated that the CBPDHAT mutant has an ability to physically interact with co-expressed E2F-1 identical to that of the wild type CBP protein. CBPDHAT is thus capable of protein/protein interactions and thus of bridging E2F to the basal transcriptional machinery, but is not able to modify histones or acetylate transcription factors.
CBP HAT domain is necessary for E2F transcriptional activity
The involvement of the CBP HAT domain in the cooperation between CBP and E2F was ®rst assessed in transient transfection assays. Expression vectors for CBP or CBPDHAT were transfected into cells, together with an E2F-luciferase reporter construct. Whereas expression of the wild type CBP molecule increased the activity of the reporter (Figure 4b) , expression of the CBPDHAT mutant did not. Interestingly, the CBPDHAT mutant instead behaved as a negative transdominant mutant, decreasing the level of reporter activity. Note that this mutant is expressed in cells at levels similar to those observed for the wild type molecule (Figure 4c ), and is, as expected, localized in the nucleus (data not shown). Similar results were observed in the CREB model system (Figure 4a ), for which the involvement of CBP HAT activity has previously been demonstrated (Korzus et al., 1998) . Taken together, these results suggest that CBP HAT activity is required for cooperation with E2F. In order to further con®rm this interpretation, the expression vector for the CBPDHAT mutant was used in antibody-microinjection experiments. Cells were microinjected with anti-CBP/p300 or irrelevant antibodies, together with the E2F-GFP reporter vector, recombinant E2F-1 protein, and an expression vector for either the wild type CBP or the CBPDHAT mutant (an empty vector was used as a negative control). Ectopic expression of wild type CBP restored GFP expression to normal levels (Figure 5a,b) , whereas expression of the CBPDHAT mutant was unable to do so ( Figure  5a,b) . This result strongly suggests that CBP HAT activity is absolutely required for cooperation with E2F.
CBP HAT domain is required for the G1/S transition
We next analysed the involvement of CBP/p300 HAT domain in the G1/S transition. Synchronized cells were microinjected with anti-CBP antibodies together with expression vectors for CBP or CBPDHAT (Figure 4 ). Ectopic expression of the CBPDHAT mutant was unable to restore the G1/S transition in cells microinjected with anti-CBP/p300 antibodies, whereas the wild type molecule was able to do so (Figure 6 ), strongly suggesting the involvement of CBP HAT activity in the G1/S transition.
Discussion
Our results lend weight to the hypothesis that CBP HAT activation is critical for the G1/S transition and is involved in the cooperation with E2F. Indeed, anti-CBP/p300 antibodies block the G1/S transition when microinjected into cells. The speci®city of the block was demonstrated by the restoration of the G1/S transition to normal levels by ectopic expression of CBP. The mechanism of action of CBP/p300 in the G1/S transition seems, at least in part, to involve cooperation with E2F, a transcription factor critical for S phase entry. Indeed, microinjection of anti-CBP/p300 antibodies into individual cells inhibited the transactivation of an E2F-GFP reporter by the E2F-1 protein.
Again, the activity of the E2F-GFP reporter was restored by ectopic expression of CBP, indicating that the inhibition was speci®c. Further analysis of the mechanism of CBP/p300 involvement in the G1/S transition suggested the involvement of CBP/p300 HAT enzymatic activity in the process. Indeed, CBP/ p300 is able to function as a co-activator either by providing a bridge between sequence speci®c transcription factors or by using its HAT activity, through chromatin remodelling or transcription factor acetylation. In order to discriminate between these two possibilities, we have designed a mutant of CBP which does not have any detectable histone acetyl transferase activity, but which interacts normally with E2F and with the basal transcription factor TBP. This mutant was unable to restore a normal level of E2F activity. This mutant was also unable to restore the G1/S transition in microinjected cells. This result indicates that the G1/S transition and E2F activity show the same sensitivity to alterations of the HAT domain, lending weight to the hypothesis that the two events are functionally linked, and that it is through cooperation with E2F that CBP/p300 participates in the G1/S transition. CBP/p300 is widely considered as the product of a tumour suppressor gene. CBP, like the anti-oncogene product Rb, is an essential target of transforming viral proteins. In addition, it is a key element in multiple cell dierentiation pathways, including muscle, myeloid cells, B cells, melanocytes, keratinocytes and others Hasegawa et al., 1997; Kitabayashi et al., 1998; Mink et al., 1997; Missero et al., 1995; Puri et al., 1997a,b; Sartorelli et al., 1997; Sato et al., 1997) . It is also a co-activator for p53, the product of a tumour suppressor which is a strong repressor of cell proliferation (Gu et al., 1997; Lill et al., 1997; Scolnick , 1997) . Similarly, it is also involved in the activity of members of the nuclear receptor family (Chen et al., 1997; Kamei et al., 1996; Torchia et al., 1997) , some of which are likewise potent inhibitors of cell proliferation. In addition, p300 mutations have been described in two cases of human tumours; and CBP is a component of fusion proteins causative of some leukaemias (Muraoka et al., 1996; Satake et al., 1997; Taki et al., 1997) . Finally, in a few examples p300 has been shown to repress cell transformation, for example by E1A (Smits et al., 1996) . Thus CBP/p300 is widely considered to be a tumour suppressor, which should repress normal cell proliferation and/or activate cell dierentiation (Giles et al., 1998; Shikama et al., 1997) , although this has not been experimentally demonstrated.
Our results indicate that CBP/p300 is critical for the G1/S transition and hence for cell proliferation, thus standing in contrast to the widely accepted idea that CBP/p300 is the product of a tumour suppressor gene: far from repressing cell proliferation, as anti-oncogene products do, CBP/p300 actively participates in the cell proliferation process. Several other observations suggest that CBP/p300 is involved in cell proliferation. First, ®broblasts from p300 7/7 embryos show defects in cell proliferation (Yao et al., 1998) , although this approach did not give any clue as to the mechanism of CBP/p300 involvement in proliferation. Second, CBP is a co-activator for the transcription factor E2F. In addition, it should be noted that, contrary to what is described for known anti-oncogenes, mutations of CBP/p300 in human tumours seem to be very rare, and have not been characterized functionally. Along these lines, it is not known whether, in fusion proteins causative of leukaemias, the CBP or p300 moiety is aected by a gain or a loss of function. Also, even though both Rb and p300/CBP are targets of transforming viral proteins, the physical interaction between these proteins and Rb or p300/CBP could have opposite eects. Indeed, whereas it is clear that E1A represses Rb activity, the eect of E1A on CBP directed transcription is a matter of controversy. For some promoters, E1A has been reported to repress CBP (Arany et al., 1995; Lundblad et al., 1995) , but E1A instead activates CBP when assayed on cell cycle related promoters such as PCNA (Karuppayil et al., 1998; Lee and Mathews, 1997) . In addition, in vitro observations indicate that E1A, at least at an equimolar ratio with CBP, behaves as an activator for CBP HAT enzymatic activity (Ait-Si-Ali et al., 1998a; Li et al., 1999) and it is only at higher molar ratios that E1A seems to inhibit this activity (Chakravarti et al., 1999; Hamamori et al., 1999) .
In any case, CBP/p300 is a versatile co-regulator involved in the`opposing' pathways of cellular proliferation and dierentiation. Proteins involved in cell fate control are generally turned on when a speci®c pathway is triggered in cells. These control proteins are functional in a given pathway, and are inactivated when cells are oriented toward other pathways. For example, Rb and the other pocket proteins are active in dierentiating cells but are inactivated by phosphorylation when the proliferation pathway is triggered. A similar pattern of regulation is observed with other proteins involved in the control of cell fate which are switched, through various pre-or post-translational modi®cations, from an active to an inactive form when cells engage in a speci®c pathway. Our results suggest that CBP/p300 is an exception: it is critical for both cell dierentiation and cell proliferation. Note, however, that although CBP/p300 is found in large complexes which include some of the components of the basal transcriptional machinery, it cannot be equated with a basal transcription factor: it is only expressed in multi-cellular organisms (Eckner, 1996) ; it is a target for transforming viral proteins and, in mammalian cells, it is required only at certain stages of development.
CBP/p300 versatility raises the interesting issue of its regulation: indeed, CBP/p300 has to be directed toward selected target genes during speci®c processes. Given the strong gene dosage eects observed with CBP/p300 (Tanaka et al., 1997; Yao et al., 1998) , a simple competition between transcription factors for CBP/ p300 binding might participate in the regulation. In addition, phosphorylation might also participate in modulation of CBP/p300 (Ait-Si-Ali et al., 1998a).
Materials and methods
Microinjections
Anti-CBP antibodies were produced by immunization of rabbits with GST-CBP protein (Ait-Si-Ali et al., 1998b) and were puri®ed using the MabTrap GII Kit (Pharmacia Biotech). These antibodies are directed essentially against the N-terminal domain of CBP (amino-acid 1 ± 1286), recognize both p300 and CBP (data not shown) and do not interfere with E2F binding to DNA, as assessed in gel-shift experiments (data not shown). NIH3T3 cells were grown on cover slips. All antibodies, proteins and plasmids were microinjected in a buer containing 10 mM Tris pH 7.4, 100 mM KCl. NIH3T3 cells were microinjected with a mixture of BSA-Rhodamine (1%; Molecular probes) as a microinjection marker and either CBP polyclonal antibodies (®nal concentration at 5 mg/ml) or rabbit Igs (for the negative control at the same concentration), with or without pCMV 2N3T-CBT (Ramirez et al., 1997) or the empty vehicle vector, at 2 mg/ml ®nal concentration. For analysis of E2F activity, cells received in addition an E2F-driven GFP reporter construct (2 mg/ml ®nal concentration) and GST or GST-E2F proteins (300 mg/ml). For analysis of the G1/S transition, cells were pulsed 9 ± 10 h later for 2 h with BrdU, ®xed using 4% paraformaldehyde, treated for 10 min with 0.5% Triton and labelled with anti-BrdU antibodies using the kit from Amersham.
Transient transfections
pCMV2N3T CBPDHAT was constructed by partial digestion of pCMV2N3T CBP (Ramirez et al., 1997) with Bst1107I ± ScaI. pGal4-luciferase was previously described (Ramirez et al., 1997) . Gal4-CREB 102 ± 151 expression vector is a kind gift of Dr Tony Kouzarides. Transient transfections were performed by calcium phosphate precipitation using standard procedures, in 12-well plates, with reporters (pGal4-luc: 500 ng/well; E2F-luc: 1 mg) and expression vectors (pGAL4 CREB, 2 mg; pPKA-CAT: 2 mg; pCMV 2N3T CBP or CBPDHAT: 2 mg). Cells also received 500 ng of pCH110 (pSV b-Gal) as a transfection control. Extracts were assayed 24 h later for luciferase and beta-Gal using kits from Promega and Tropix, respectively. Luciferase activities were standardized by reference to the beta-Gal activity and foldactivation by CBP or CBPDHAT were calculated by reference to the values obtained with the empty control vector.
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HAT assays
HAT assays were performed as previously described (Ait-SiAli et al., 1998b), using about 100 pmoles of GST recombinant proteins.
GST pull down analysis
GST and GST-CBP vectors were described previously (AitSi-Ali et al., 1998b). GST-CBPDHAT was constructed by inserting CBPDHAT cDNA from pCMV2N3T into pGEX2T. Fusion proteins were prepared as described (AitSi-Ali et al., 1998a) . GST, GST-CBP and GST-CBPDHAT coated beads were prepared as previously reported (Groisman et al., 1996) . Beads were pre-incubated with rabbit reticulocyte lysate (Promega), incubated with equivalent amounts of either in vitro translated 35 S-methionine labelled E2F1 or bacterial His-TBP protein. For CBP/E2F1 pulldown, bound proteins were analysed by SDS ± PAGE followed by autoradiography. For CBP/TBP pull-down, bound proteins were separated by SDS ± PAGE and analysed by Western blotting with an anti-polyhistidine antibody (Santa Cruz).
Immunoprecipitation and Western blot
COS cells were transfected with pCMV 2N3T-CBP, pCMV 2N3T-CBPDHAT or pCMV 2N3T. Forty-eight hours later, cell extracts were submitted to immunoprecipitation with anti-HA monoclonal antibodies (12CA5) followed by Western blot analysis using the same anti-HA antibody as described in Magnaghi-Jaulin et al. 1998) . For co-immunoprecipitation, C3H 10T1/2 cells were transfected with pCMV 2N3T-CBP, pCMV 2N3T-CBPDHAT or pCMV 2N3T together with an E2F-1 expression vector.
